MX2023005303A - Inhibidor de raf para el tratamiento del glioma de bajo grado. - Google Patents
Inhibidor de raf para el tratamiento del glioma de bajo grado.Info
- Publication number
- MX2023005303A MX2023005303A MX2023005303A MX2023005303A MX2023005303A MX 2023005303 A MX2023005303 A MX 2023005303A MX 2023005303 A MX2023005303 A MX 2023005303A MX 2023005303 A MX2023005303 A MX 2023005303A MX 2023005303 A MX2023005303 A MX 2023005303A
- Authority
- MX
- Mexico
- Prior art keywords
- low grade
- sup
- grade glioma
- compound
- raf inhibitor
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 208000030173 low grade glioma Diseases 0.000 title 1
- 229940126062 Compound A Drugs 0.000 abstract 3
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 abstract 3
- 208000027059 pediatric low-grade glioma Diseases 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 206010018338 Glioma Diseases 0.000 abstract 1
- VWMJHAFYPMOMGF-ZCFIWIBFSA-N TAK-580 Chemical compound N([C@H](C)C=1SC(=CN=1)C(=O)NC=1N=CC(Cl)=C(C=1)C(F)(F)F)C(=O)C1=NC=NC(N)=C1Cl VWMJHAFYPMOMGF-ZCFIWIBFSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
En la presente se describen métodos y composiciones para tratar gliomas como el glioma pediátrico de bajo grado. En algunas modalidades, un método de tratamiento del glioma pediátrico de bajo grado descrito en la presente comprende administrar a un sujeto en necesidad del mismo (R)-2-(1-(6-amino-5-cloropirimidina- 4-carboxamido)etil)-N-(5- cloro-4-(trifluorometil)piridin-2-il)tia zol-5-carboxamida (Compuesto A) o una sal farmacéuticamente aceptable de la misma. En algunas modalidades, el Compuesto A o una sal farmacéuticamente aceptable del mismo se administra en una cantidad que es equivalente a aproximadamente 400 mg/m2 hasta aproximadamente 600 mg/m2 de Compuesto A por semana. En algunas modalidades el sujeto es de menos de 20 años de edad.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063110724P | 2020-11-06 | 2020-11-06 | |
| US202163138285P | 2021-01-15 | 2021-01-15 | |
| PCT/US2021/058337 WO2022099074A1 (en) | 2020-11-06 | 2021-11-05 | Raf inhibitor for treating low grade glioma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023005303A true MX2023005303A (es) | 2023-09-12 |
Family
ID=81457433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023005303A MX2023005303A (es) | 2020-11-06 | 2021-11-05 | Inhibidor de raf para el tratamiento del glioma de bajo grado. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230355618A1 (es) |
| EP (1) | EP4240354A4 (es) |
| JP (1) | JP2023548600A (es) |
| KR (1) | KR20230107606A (es) |
| AU (1) | AU2021376286A1 (es) |
| CA (1) | CA3200986A1 (es) |
| MX (1) | MX2023005303A (es) |
| WO (1) | WO2022099074A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023056063A1 (en) * | 2021-10-01 | 2023-04-06 | Day One Biopharmaceuticals, Inc. | Raf kinase inhibitors for treating tumors harboring gene fusions |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104428001A (zh) * | 2012-03-30 | 2015-03-18 | 武田药品工业有限公司 | Raf抑制剂和mek抑制剂在黑素瘤治疗中的投与 |
| UY36046A (es) * | 2014-03-26 | 2015-10-30 | Millennium Pharm Inc | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso |
| CA2972076A1 (en) * | 2014-12-23 | 2016-06-30 | Millennium Pharmaceuticals, Inc. | Combination of raf inhibitors and aurora kinase inhibitors |
| PT3319993T (pt) * | 2015-07-10 | 2020-04-22 | Genmab As | Conjugados de anticorpo-fármaco específicos de axl para tratamento de cancro |
| WO2018220533A2 (ja) * | 2017-05-30 | 2018-12-06 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | 光学活性化合物の製造法 |
-
2021
- 2021-11-05 JP JP2023527333A patent/JP2023548600A/ja active Pending
- 2021-11-05 KR KR1020237018911A patent/KR20230107606A/ko unknown
- 2021-11-05 EP EP21890193.2A patent/EP4240354A4/en active Pending
- 2021-11-05 WO PCT/US2021/058337 patent/WO2022099074A1/en active Application Filing
- 2021-11-05 MX MX2023005303A patent/MX2023005303A/es unknown
- 2021-11-05 US US18/035,478 patent/US20230355618A1/en active Pending
- 2021-11-05 AU AU2021376286A patent/AU2021376286A1/en active Pending
- 2021-11-05 CA CA3200986A patent/CA3200986A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022099074A1 (en) | 2022-05-12 |
| EP4240354A4 (en) | 2024-07-17 |
| AU2021376286A1 (en) | 2023-06-22 |
| CA3200986A1 (en) | 2022-05-12 |
| JP2023548600A (ja) | 2023-11-17 |
| KR20230107606A (ko) | 2023-07-17 |
| US20230355618A1 (en) | 2023-11-09 |
| EP4240354A1 (en) | 2023-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023007192A (es) | Inhibidores de prmt5. | |
| MX2023009222A (es) | Inhibidores tricíclicos-amido-bicíclicos de prmt5. | |
| JPS62242617A (ja) | 目の炎症の治療薬 | |
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| KR970704435A (ko) | 헤테로시클릭 화합물의 도파민-D 리간드로서의 용도(Use of Heterocyclic Compounds as Dopamines-D Ligands) | |
| RS53767B1 (en) | PROCEDURE FOR TREATMENT OF JOINT INJURY | |
| JP2009513713A5 (es) | ||
| MX2022013647A (es) | Imidazopiridazinas como moduladores de il-17. | |
| MX2022012923A (es) | Inhibidores de trpc6 para tratar afecciones respiratorias. | |
| MX2023005303A (es) | Inhibidor de raf para el tratamiento del glioma de bajo grado. | |
| MX2024000234A (es) | Inhibidores del inflamasoma nlrp3. | |
| MX2024003770A (es) | Compuestos de imidazopiridazina inhibidores de il-17. | |
| UA74788C2 (en) | Ophthalmic composition comprising ketotifen for treating allergic conjunctivitis | |
| RU2004114560A (ru) | Комбинации, включающие ингибиторы сох-2 и аспирин | |
| MX2023013225A (es) | Inhibidores de la cinasa 4 similar a polo. | |
| US11564910B2 (en) | Drug compositions | |
| MX2023003332A (es) | Inhibidores del elemento 1 interdispersado largo (line-1) para el tratamiento de enfermedades. | |
| WO1997041864A1 (fr) | Preparations ophtalmiques | |
| JP5776355B2 (ja) | 内服液剤 | |
| WO2010107791A4 (en) | Pyrazinoisoquinoline compounds | |
| MXPA05008711A (es) | Uso de r-10-hidroxi-10,11-dihidro-carbamazepina en dolor neuropatico. | |
| WO2015055974A1 (en) | Proton pump inhibitor paste compositions | |
| RU2006131788A (ru) | Микроэмульсионные композиции, включающие антагонисты вещества р | |
| CN111479567A (zh) | 包含FP激动剂和β-阻断剂的青光眼的治疗剂 | |
| JP2020100576A (ja) | 皮膚外用組成物 |